Angiopoietin-2 Differentially Regulates Angiogenesis Through TIE2 and Integrin Signaling
Overview
Authors
Affiliations
Angiopoietin-2 (ANG-2) is a key regulator of angiogenesis that exerts context-dependent effects on ECs. ANG-2 binds the endothelial-specific receptor tyrosine kinase 2 (TIE2) and acts as a negative regulator of ANG-1/TIE2 signaling during angiogenesis, thereby controlling the responsiveness of ECs to exogenous cytokines. Recent data from tumors indicate that under certain conditions ANG-2 can also promote angiogenesis. However, the molecular mechanisms of dual ANG-2 functions are poorly understood. Here, we identify a model for the opposing roles of ANG-2 in angiogenesis. We found that angiogenesis-activated endothelium harbored a subpopulation of TIE2-negative ECs (TIE2lo). TIE2 expression was downregulated in angiogenic ECs, which abundantly expressed several integrins. ANG-2 bound to these integrins in TIE2lo ECs, subsequently inducing, in a TIE2-independent manner, phosphorylation of the integrin adaptor protein FAK, resulting in RAC1 activation, migration, and sprouting angiogenesis. Correspondingly, in vivo ANG-2 blockade interfered with integrin signaling and inhibited FAK phosphorylation and sprouting angiogenesis of TIE2lo ECs. These data establish a contextual model whereby differential TIE2 and integrin expression, binding, and activation control the role of ANG-2 in angiogenesis. The results of this study have immediate translational implications for the therapeutic exploitation of angiopoietin signaling.
Yanai R, Yasunaga G, Tsuji S, Honda T, Iwata A, Miyagawa E FASEB J. 2025; 39(4):e70378.
PMID: 39937567 PMC: 11818653. DOI: 10.1096/fj.202402041R.
Castanho I, Yeganeh P, Boix C, Morgan S, Mathys H, Prokopenko D bioRxiv. 2025; .
PMID: 39868232 PMC: 11761133. DOI: 10.1101/2025.01.13.632801.
Kiesworo K, Agius T, MacArthur M, Lambelet M, Lyon A, Zhang J iScience. 2025; 28(1):111656.
PMID: 39868046 PMC: 11763620. DOI: 10.1016/j.isci.2024.111656.
Vienot A, Vernerey D, Bouard A, Klajer E, Kim S, Tournigand C Cancer Res Commun. 2025; 5(2):287-294.
PMID: 39807836 PMC: 11811826. DOI: 10.1158/2767-9764.CRC-24-0246.
Vakili S, Cao K Int J Mol Sci. 2025; 25(24.
PMID: 39769300 PMC: 11676795. DOI: 10.3390/ijms252413537.